Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.824208
Keywords
glypican-3 (GPC3); hepatocellular carcinoma (HCC); cancer immunotherapy; immune checkpoint blockade; chimeric antigen receptor
Categories
Funding
- National Natural Science Foundation of China [31971390]
- Sichuan Science and Technology Program [2021YFH0142]
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYJC21043]
Ask authors/readers for more resources
GPC3 is specifically up-regulated in hepatocellular carcinoma and has shown promising value in diagnosis and treatment. GPC3-based therapeutic methods such as vaccines, immunotoxins, and CAR T or NK cells have emerged with exciting results.
Glypican-3 (GPC3) is a membrane-associated proteoglycan that is specifically up-regulated in hepatocellular carcinoma (HCC) although rarely or not expressed in normal liver tissues, making it a perfect diagnostic and treatment target for HCC. Several GPC3-based clinical trials are ongoing and recently several innovative GPC3-targeted therapeutic methods have emerged with exciting results, including GPC3 vaccine, anti-GPC3 immunotoxin, combined therapy with immune checkpoint blockades (ICBs), and chimeric antigen receptor (CAR) T or NK cells. Here, we review the value of GPC3 in the diagnosis and prognosis of HCC, together with its signaling pathways, with a specific focus on GPC3-targeted treatments of HCC and some prospects for the future GPC3-based therapeutic strategies in HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available